Abstract
Abstract
Background
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have significantly improved survival outcomes of advanced non-small cell lung cancer (NSCLC). Nonetheless, usage of TKIs is not without adverse effects, as it has been reported to cause irreversible sensorineural hearing loss (SNHL).
Case presentation
We describe a 72-year-old man who experienced hearing loss after taking osimertinib for 6 months. Later, his hearing further declined over a period of 1 year. Hearing rehabilitation with high-powered behind-the-ear (BTE) hearing aid has helped to improve his quality of life to some degree. There were no other known causative factors leading to the hearing deterioration. To date, there is no case report on osimertinib-induced SNHL.
Conclusion
Physicians ought to counsel patients on osimertinib of this rare side effect and monitor for early signs of hearing loss. Treatment protocol should be in place taking into account that they have either failed or likely to fail the first- or second-line treatments and have advanced stage disease.
Publisher
Springer Science and Business Media LLC
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Osimertinib;Reactions Weekly;2023-05-27